Opdivo Overtakes Keytruda, Fueled By Lung Cancer Use
Executive Summary
In the second quarter, Bristol notes rapid uptake for PD-1 inhibitor Opdivo in lung cancer, while Merck touts dominant position in U.S. melanoma market for its competing Keytruda.